The document profiles Sabin C. Carme, a transdisciplinary scientist with experience in industry R&D, innovation, and business. It discusses two company cases he has evaluated: PAPE, which involves a drug delivery system using local palladium activation for low toxicity therapy, and opportunities for building strategic advantages. It also includes an analysis of the company's competitive advantage, business model, market forces, strengths, weaknesses and opportunities for further assessment.

1. Nutopya
Company Creation Unit
Sabin C. Carme

2. BACKGROUND
PhD
Paris LyonTrondheim LondonDijon
MBA
Industry R&D Innovation Business
8 years 4 years
Training

3. 3
2
11# Transdisciplinary
Scientist
SKILLS
2# Innovation
Facilitator
3# Mindset
Entrepreneur
CASE
STUDY

4. DUE-DILLIGENCE
Information Gathering Decision Making

5. Information gathering

6. COMPANY CASE « PAPE »
Drug delivery > Local Palladium activation
for low toxicity therapy

7. COMPANY CASE « PAPE »
Drug delivery > Local Palladium activation
for low toxicity therapy

8. COMPANY CASE « PAPE »
« combined products »
= Marketing approvals for each combination

9. COMPANY CASE « PAPE »
« combined products »
= Marketing approvals for each combination

10. COMPANY CASE « PAPE »
Opportunities = LCM + New device market + Injectable
Possibility to build a strategic advantage

11. MARKET & SALES

12. MARKET & SALES
Financial Figures
+- 50M$ business

13. PEOPLE & PARTNERSHIPS
- 1M£ ESPRC Award
- Deliverics (Scottish Enterprise,
Innova Partnerships Ltd and Upstarts UK Ltd)
Dr Jason Weiss

14. FUNDAMENTALS
> Preclinical POC
> Patent and FTO
> Manufacturing costs Palladium
Cost, pure: $60.000 per Kg
Cost, bulk: $15.00 per Kg
> Safety
Reduce synthesis steps
Palladium ADME : torelability profile safe

15. Decision Making

16. COMPETITIVE ADVANTAGE
Safe
Therapy
Cost
effective
Clinical
POC
Market
Value
First
in Man
Concept
Chemotherapy
Targeted therapy
Brachytherapy

17. BUSINESS MODEL CANVAS
CRO
PreCllinical
CMO
Manufacturing
Accounting
Finance
Project
management
VC investors
seed
Expert consultant
- Regulatory
- Health-economy People
IT / Software / Cloud
- Project
- Data
- Customer
Pharma industry
co-developper
Outsourcing
- Contractors
- Collaborators
Partnering / promoting
- Pharma industry
- Investors
Staff – FTE + Ops
- 3 Managers
- 3 Technicians
Hospital trial
site
Device company
Nanoscience
research
IP
Know-how
VC investment
FFF investment
Public
subventions
Grants
Pharma
Co-developement
upfront
Business
conventions
Networking
Mentorship
Medical KOL
Experts
A solution
combination of
prodrugs and
device for safe
chemotherapy
POC of drug
candidate
Expert company in
drug/device
combination
product
Medical Doctor
Early adopters
Cost-
effectiveness
Pitch
Due-dilligence
Investors focused Business dev
Academic Lab

18. • Bridging biology, physic and chemistry leads to innovation
• Manufacturing and control is challenging as compared to standard drug production
• With recents crisis governments have policies to reduced the medical
expenses and drug reimbursements (Obama in USA has launched the
affordable care act)
• Governement creates more agencies and facilitators for biotech start-up take
off and seed capital to better survive the valley of death
• Biotech companies compete to attract investors and communicate on their
activities via the press platforms and social media (Linked in, twitter, blogs…)
• Stock market emphasize biotech success story such as Gilead or Biogen idec in
newspapers
• New nanomedicine have unknown safety risks that requires lcontingencies plan
• New medicine development needs to settle agreement between public private
institutions (academia, hospitals)
• As the technology s sourced from academia, it is important to define a strategy
that ensure market access for patient cure instead of pursuing medical research
that only benefit academic scientists
• Production and manufacturing should be respectful for environment policies
• Medical doctors expect from us to provide their patients therapy for incurable
disease and reduce side effects and patient burden of chemotherapy
• Not all patients will be able to pay the price for the new medicine, the therapy
affordability for the maximum of patient is key
• Biomedical industry is a business that is growing with the longer life expectancy,
and middle class wealth both leading to cancer incidence increase.
• The recent IPO in biotech has allowed severals VCs to exit and create new funds
for investing during 2015-2020
PESTL

19. RIVALRY
High
Lots of biotechs seeking for
capital investment and co-
development with biomedical
industry Importance of niche
combination product
NEW ENTRANTS
High
Lots of medicine innovation for the same
cancer indications. Targeted reduce toxicity
SUBSTITUTES
Low
Incremental innovation and life cycle
management of existing biomedical therapy
fail for safer medicine
SUPPLIERS
Externalization
With more project management
of outsourcing and ecosystem
of service providers
BUYERS
Pharma in-licensing
Need to demonstrate cost
effectiveness of the new medicine
and importance of adressing
incurable rare disease
PORTER 5 FORCES

20. INDUSTRY
PROFITABILTIY
RELATIVE FIRM
PROFITABILITY
Opportunity Threats
Strength Weakness
- Cost effective and need for safer
chemotherapy
- Life Cycle management of
existing out of patent drugs
- VC funds looking for investment
in 2015-2020
- Competition of different targeted
technology and medical devices on
similar indications
- Regulation in the combination product
field
- No team member outside of academia
- IP and Know-how
- Network of academia and
clinicians
- Supporting company process
at SUNERGOS
- Need confirmatory data aligned with
pharma industry needs
- Network of mentors and advisors for
endorsment
- Regulatory and pharmacoeconomy
expertise
SWOT

21. SCORE

22. DECISION ANALYSIS

23. HIGHLIGHTS
> Score is above average 3.3 should be taken carefully and not reflect on
the project potential but more on the missing information tat is necessary
to support the project
> Team members with business background, validation of business area
interest from pharma, regulatory feasibility of combination products, IP
rights and freedom to operate on prodrugs.
> The PAPE project with outstanding scientists support and huge demand
from patients has a fantastic potential that requires to conduct further and
deeper assessment.

24. Bridge Disciplines
• Imaging MRI / Nuclear / Optical
• Radiation therapy
• Pharmacology
• Clinical research
• Complex Data Modeling
• Algorithm Programing
• Nanomedicine / Bioconjugates
• Molecular Biology
Invention Commercialization
• Client Need analysis / prospect / sales
• Build Trust with Scientist Team
• Pre-competitive consortium
• Agreement / Contracts
• Patent / IP rules / FTO
• Grant/Subventions application
Identify Opportunities
• Market analysis
• Business Model Design
• Fundraising strategy
• Start-up Operation / KPIs
ASSESS OPPORTUNTIES
FOR INVESTMENT DECISION

25. sabin.carme@qwest-science.com https:www.nutopya.com
Sabin C. Carme
w

26. sabin.carme@qwest-science.com https:www.nutopya.com
Sabin C. Carme
w

27. sabin.carme@qwest-science.com https:www.nutopya.com
Sabin C. Carme
w